




RealRate

# MEDICINAL PRODUCTS 2021

Celldex Therapeutics Inc.  
Rank 19 of 52





RealRate

# MEDICINAL PRODUCTS 2021

## Celldex Therapeutics Inc. Rank 19 of 52



The relative strengths and weaknesses of Celldex Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celldex Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Celldex Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 67%, being 122% points above the market average of -55%.

Input Variable	Value in 1000 USD
Assets, Current	197,843
Assets, Non-Current	3,490
General and Administrative Expense	14,456
Goodwill	30,690
Liabilities, Current	14,206
Liabilities, Non-Current	12,275
Other Assets	0
Other Compr. Net Income	-59,810
Other Expenses	12,615
Other Liabilities	0
Other Net Income	-30
Other Revenues	9,825
Property, Plant and Equipment, Net	3,815
Research and Development	42,534

Output Variable	Value in 1000 USD
Liabilities	26,481
Assets	235,838
Expenses	69,605
Revenues	9,825
Stockholders Equity	209,357
Net Income	-59,810
Comprehensive Net Income	-89,715
Economic Capital Ratio	67%